Advances in Pharmacology and Pharmacy
The purpose of this retrospective chart review was to determine the correlation between full weight-based enoxaparin use and the frequency of anti-Xa concentrations within the defined therapeutic range; to ascertain if anti-Xa monitoring is being appropriately ordered in relation to the timing of enoxaparin dose (after 3 consistent therapeutic doses and 3-5 hours post-dose); to establish if the evidence-based recommended dose adjustment protocol that was studied in the pediatric population was utilized; and if this yielded anti-Xa concentrations within the target range (0.6 – 1.1 IU/mL) for an adult population. The data may suggest a lack of correlation between BMI and whether or not the anti-Xa concentration is within the therapeutic range. Further prospective studies are needed to confirm this finding, and to determine the utility of the available dose adjustment nomogram.
Originally published by Horizons Research under a creative commons attribution license in Advances in Pharmacology and Pharmacy, 2014, Volume 1, Issue 2. DOI: 10.13189/app.2013.010201
Levine, Lauren; Pallme, Nicole; Angelotti, Erik; and Shiltz, Dane L., "Analysis of Anti-Xa Concentrations in Patients on Treatment Dose Enoxaparin: a Retrospective Chart Review" (2013). Scholarship and Professional Work – COPHS. 65.